Open AccessEndothelin-Converting Enzyme Inhibitors: Current Status and Perspectives
Author(s) -
Bernd–Michael Löffler
Publication year - 2000
Publication title -
journal of cardiovascular pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-200000002-00018
Subject(s) - endothelin receptor , renin–angiotensin system , angiotensin converting enzyme , enzyme , endothelin 1 , pharmacology , homeostasis , angiotensin converting enzyme 2 , chemistry , medicine , endocrinology , biology , biochemistry , blood pressure , receptor , disease , covid-19 , infectious disease (medical specialty)
Recent research has led to the discovery of potent selective or mixed endothelin-converting enzyme (ECE), ECE/neutral endopeptidase24.11 (NEP) and ECE/NEP24.11/angiotensin-converting enzyme (ACE) inhibitors. There is also increasing evidence, that the functions of the endothelin (ET), renin-angiotensin and NEP systems for the regulation of the cardiovascular homeostasis are connected by a complex regulation network. It will be the challenging task of future research with the newly available selective and mixed ECE-1 inhibitors to show whether the combined inhibition of more than one cardiovascular system is superior to selective inhibition.